focus -WSS

focus

author：comprehensive 2025-09-27 23:53:21 - browse：91

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Virtual Event: March of the Biosimilars

leisure time

WSS

Will General Catalyst be the first of many hospital takeovers?

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

More doctors should go into startup world

MoonLake credibility takes another hit with mid

Virtual Event: March of the Biosimilars

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

How one medical school became remarkably diverse

Future doctors should be trained to promote social change

Hollywood unions extend contract negotiations for actors

Creating egg and sperm cells from stem cells raises ethical issues

After affirmative action ruling, medical educators look to 'holistic review'

Removing probiotics from the NICU could threaten preemies' health

BioMarin wins approval for gene therapy to treat hemophilia A

Stop the failed accountable care organization experiment

Medicare proposal to cover medical devices draws a mixed reaction

Medicare solvency divides Republicans at the presidential debate

focus

Orchard's therapy for neuron disease in children wins FDA approval

Nurses recount patients attacks

STAT Executive Editor Rick Berke on STAT's 8th birthday

More doctors should go into startup world

Senate panel clears PBM, hopsital reforms

Senate panel clears PBM, hopsital reforms

leisure time

hotspot

hotspot

focus